Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 
 
 

Horizon Discovery launches new companion diagnostics venture
February 2010
SHARING OPTIONS:

CAMBRIDGE, England—Translational genomics firm Horizon Discovery announced in January that it has formed a new subsidiary venture, Horizon Dx Ltd. (HDx), to support the development, approval and sale of companion diagnostic products initially in the field of cancer. At the center of the venture will be Horizon's panel of more than 175 human isogenic cell models that recapitulate key drug sensitivity and resistance mechanisms in cancer patients. The first commercial products supplied by the new venture will be genetically defined mutant DNA and isogenic cell-admixtures situated within formalin fixed paraffin embedded samples. These control reagents will be used in conjunction with companion diagnostic kits that are currently enabling clinicians to ascertain which patients will respond to novel cancer therapies. Horizon is initially funding HDx from its balance sheet, but hopes to secure a multi-million dollar investment into the company by the end of the first half of 2010.
 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.